Lexicon Pharmaceuticals, Inc. (LXRX)
Automate Your Wheel Strategy on LXRX
With Tiblio's Option Bot, you can configure your own wheel strategy including LXRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LXRX
- Rev/Share 0.0862
- Book/Share 0.3398
- PB 1.8293
- Debt/Equity 0.3418
- CurrentRatio 2.2206
- ROIC -0.7744
- MktCap 225751445.0
- FreeCF/Share -0.4653
- PFCF -1.3401
- PE -1.2694
- Debt/Assets 0.1413
- DivYield 0
- ROE -1.0316
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LXRX | Leerink Partners | Outperform | Market Perform | $2 | $1 | March 5, 2025 |
News
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced details of its “ SO tagliflozi N in Patients with Symptom AT ic obstructive A nd non-obstructive H ypertrophic C ardio M yopathy (SONATA-HCM)” study were presented on Saturday, May 17. The study design was disclosed in Belgrade, Serbia at one of the …
Read More
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET.
Read More
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m.
Read More
Top 2 Health Care Stocks That May Crash This Month
Published: April 25, 2025 by: Benzinga
Sentiment: Negative
As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Read More
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Read More
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Published: March 28, 2025 by: Benzinga
Sentiment: Positive
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.
Read More
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardiovascular outcomes. The findings from the study, “Reduction in Major Adverse Cardiovascular Events with Sotagliflozin: A Prespecified Analysis of the SCORED Randomized Trial,” concluded that the …
Read More
About Lexicon Pharmaceuticals, Inc. (LXRX)
- IPO Date 2000-04-07
- Website https://www.lexpharma.com
- Industry Biotechnology
- CEO Dr. Michael S. Exton Ph.D.
- Employees 103